A Randomized, Double-Blind, Three-Arm, Phase 3b Study Comparing the Safety and Efficacy of Interferon Gamma-1b With Azathioprine, and Azathioprine Alone in Patients With IPF Receiving Prednisone

InterMune

Status and phase: Terminated; Phase 3

Conditions: Pulmonary Fibrosis; Lung Disease

Treatments: Drug: azathioprine; Drug: interferon-gamma 1b

Study type: Interventional

Funder types: Industry

Identifiers

NCT00052039

GIPF-003

Details and patient eligibility

About

Study GIPF-003 is a Phase 3b study designed to define better therapeutic use of IFN-gamma 1b in patients wtih IPF. The study will be conducted primarily in Europe and will enroll 210 patients.

Sex: All

Ages: 20 to 79 years old

Volunteers: No Healthy Volunteers

Inclusion and exclusion criteria

Trial design

Primary purpose: Treatment

Allocation: Randomized

Interventional model: Parallel Assignment

Masking: Quadruple Blind